Check out a few of the 1200 attendees we had at LSI USA '23 (below) to see who we draw at our events.

I support multidisciplinary teams at the intersection of high tech and health care. From 2006 to 2019, I've lived, learned and worked with entrepreneurs, investors, universities, and corporations in Silicon Valley. I am now back in Europe, as the founder and managing partner of Nina Capital, to invest in this sector alongside a stellar international team.

Sectors and Focus:
I am especially committed to innovation in information technology / digital health, and have broader expertise in health technology and medical devices with emphasis on needs and markets identification, product management, regulation (FDA Class I-II), fundraising and growth strategies of early-stage companies.

Personality:
I have a bias towards entrepreneurs and an appetite for continuous learning. Leveraging my technology and business domain expertise, I have the most fun while mentoring young professionals and contributing to the building of products and companies. I thrive in unstructured environments, where the risks are high and success hinges on creative people with high ethical standards to self-organize and work together towards solving a compelling health care need.

Philosophy and Goals:
I believe in a culture of collaboration and giving, and in the ripple effect in all aspects of life or business. Keeping my values close and my loved ones even closer, I am moved by a desire to make positive impact and serve a community of health tech innovators, so that their inspiring ideas become solutions that matter in the hands of those who need them the most.

Background:
I have held roles with vastly different organizations in Europe, Canada and the United States, and developed my operational and creative abilities by contributing to, establishing and growing businesses.

Actively investing out of Endeavour Medtech Growth II, focusing on growth stage medical device and digital health companies in Europe and the US.

Specialities:

• Strategic Planning, Forecasting, Budgeting
• Venture Capital & Private Equity
• Medical Devices
• Product Launch Planning
• Strategy Consulting

Diana is General Partner and co-founder at Panakes Partners, an investment company focused on Innovative Early Stage Medical companies, all over Europe and more particularly in Italy (www.panakes.it).

Before, Diana was General Partner at 360 Capital Partners which she co-founded as well.
360 Capital is a Venture Capital Fund investing in Innovative early stage companies all over Europe and more particularly in Italy and France.

Before joining the Venture Capital industry almost 20 years ago, Diana was Senior Advisor at Lazard Investment Banking and primarily worked on M&A transactions and IPO in Telecom, Media & Technology .

Prior to Lazard, Diana spent over 4 years at ATKearney in Milan and London.

She graduated from the University of Rome with a degree in Engineering, and received an MBA from LUISS of Rome.

Specialties: Venture Capital financing, Scouting of new investment opportunities, Board member, M&A transactions, IPOs, companies strategic assessment.

Leads the Venture Capital program fro the corporation, and M&A / Business Development for the MedSurg divisions. As VP of Business Development, Led a team of BD professionals and cross-functional partners directing all business development efforts (acquisitions, venture investments, divestitures, distributions, licenses, and other strategic partnerships) across 5 of Boston Scientific’s 7 Divisions: Endoscopy, Urology & Pelvic Health, Neuromodulation, Cardiac Rhythm Management, and Electrophysiology (a combined $6.5B/year revenue business). Closed acquisitions ranging in size from $1.5M to $1.65B. Deployed over $250M in venture capital investments ranging in size from $1M to $50M. Represented Boston Scientific on portfolio companies’ Boards of Directors (two voting and 3 non-voting board seats).

Managing partner, president and co-founder at Asabys. Josep currently serves on the board of directors of Anaconda, Cara Care, Inbrain Neuroelectronics, Medasense, Medlumics and Psious.

Formerly, Josep co-founded Ysios Capital (2008-2018) where he was the partner in charge of Health Technology investments, investing in a total of 9 companies in the areas of medtech and digital health in Europe and in the US. Previously, Josep held positions in the pharmaceutical and home-healthcare industries as Corporate Development Director at Almirall and General Manager of DomusVi. Josep started his career in Cuatrecasas, KPMG and Eurohold.

Josep has a Degree in Law by the Universitat Pompeu Fabra, a Master of Laws (LL.M.) from the University of Michigan Law School and also an MBA from IESE Business School.

Prior to co-founding First Spark Ventures, Manish was President at SRI International, leading research institute in Silicon Valley and the birthplace of companies such as Intuitive Surgical, Nuance, and Siri. He incubated and invested in over 25 Deep Tech startups, in addition to advising translational programs with the US Government that include agencies such as NASA and Department of Education. Prior to that, he was serial entrepreneur in Medtech and software, including cofounding Mytrus, software startup focused on direct-to-participant clinical trials. It was the first company in the world to have FDA approved electronic informed consent. Manish has a postdoc from UCSF in Medical Physics, a PhD from Cornell in Bioengineering, and undergraduate from the Indian Institute of Technology, Mumbai in Aerospace Engineering.

Head of Communications at Sofinnova Partners, a leading European venture capital firm based in Paris, London, and Milan. Sofinnova manages €2.6 billion in assets across a platform of investments strategies that span multiple healthcare and sustainability domains (biotech, medtech, foodtech, greentech). I am responsible for the company's global communications strategy. If you are looking to pitch a project, please do so via our website: sofinnovapartners.com.

Bio coming soon.

Mark Slack is a co-founder and the Chief Medical Officer of CMR Surgical. He is a Consultant Gynaecologist with a strong background in clinical and translational research.

Mark trained as a medical doctor and Gynaecologist in South Africa graduating with the Gold Medal for Obstetrics and Gynaecology for the Fellowship of the College of Medicine of South Africa. He has continued to pursue a combined clinical and academic career with a number of successful innovations in surgery and Gynaecology. In addition, he has a strong interest in basic science research.

He still practices clinical medicine and surgery in Cambridge as well as being on the staff of the clinical school of medicine of the University of Cambridge.

Mark is actively involved in clinical and basic research and participates in student teaching. He also has strong academic links in the USA, Canada, Europe, Australia and South Africa. His work resulted in him being awarded the Simms Black Professorship of the Royal College of Obstetricians and Gynaecologists and the award of “Leading Clinical Researcher” by the National Institute of Health Research in 2015. He has published over a hundred original peer reviewed articles and contributed to more than 25 textbooks.

His interest in minimal access surgery led him to explore the possibilities of improving uptake of minimal access surgery by the utilisation of more sophisticated surgical tools such as the robot.

Supratim is a seasoned executive in the healthcare industry having held several senior regional and global leadership positions in reputed MedTech organisations.

Supratim brings a deep understanding of the medical technology industry, as well as significant knowledge of the Asia Pacific, Middle East and Africa, and Latin America regions. 

Over the course of his career, Supratim has held several senior leadership and growth positions in global MedTech organisations, including ConvaTec, Boston Scientific and J&J. At J&J, he served as Company Group Chairman of J&J Medical Devices and Diagnostics, and as a member of the Group Operating Committee, he was responsible for setting the strategic direction for the US$23 billion Medical Devices and Diagnostics business globally and for all the Medical Devices and Diagnostics businesses in Asia Pacific.

Prior to joining CMR, he was the President & Chief Operating Officer, Global Emerging Markets at ConvaTec. Supratim has also served as a member of the Board of Carefusion (now part of Becton Dickinson), Trireme Medical and Advisory Board of the Lee Kong Chian School of Business at Singapore Management University.

Throughout his career, Supratim has been recognised within the industry for his ability to drive growth, expand market reach, and improve operational efficiency in organisations he has served.

Bio coming soon. Prior to joining Lauxera Capital Partners, Charles Cornevin was a Senior Associate at Eurazeo where he focused on healthcare buyouts. Charles joined Eurazeo in 2017 as an Analyst after several experiences in M&A and Private Equity (Rothschild and Hudson Advisors / Lone Star Funds in Munich, Dublin and London).

Charles started his career as a generalist investor within the Eurazeo Mid-Cap team and has participated in the monitoring of the following investments: Odealim (incl. exit), Redspher, Dessange, and the Rosa Group. He then launched the Eurazeo Healthcare-dedicated strategy from scratch and completed two investments in 2021: Novair Group and PSIH.

Charles graduated from Paris Dauphine University with a Masters in Corporate Finance and Financial Engineering.

Aiming to improve people's quality of life through investing in healthcare innovation.

Philips Ventures is the corporate venture capital arm of Philips, the multinational health tech leader. Working across 3 global investment vehicles:
• Digital health fund: early-stage venture fund focused on new themes with cross-business alignment within Philips.
• Business-sponsored investments: multi-stage venture fund focused on companies that fits Philips’ core strategy.
• Fund of fund investments: portfolio of strategically aligned venture funds.

Involved in Business Development, Venture Capital Investment, Mergers & Acquisitions, Sales Management, and Marketing in Medical Device. As the Director of Strategy and New Business Development, he was responsible for development and execution of mergers, acquisitions, and venture stage investment strategy for $1B+ Urology And Pelvic Health division of Boston Scientific.

Specialties: Venture Capital Investment, Mergers and Acquisitions, Market analysis and business plan development for emerging technologies; upstream market strategy, sales management and team leadership; sales team training and development.

Marion joined our MD Start team in 2019. She is the CEO of Ablacare, after having managed the execution of the first-in-human study and regulatory approvals in the E.U. and the U.S. for the company.

She enjoys MD Start’s fast-paced, close-to-the-ground approach. “My day-to-day is operational and hands-on, focused on building products and creating value for patients and clinicians with breakthrough innovations,” she says.

Marion also plays a big part in managing the MD Start deal flow, the identification and evaluation of the most promising ideas for incubation. She says that to get a full picture of an idea's potential, the MD Start team taps into collective intelligence, talking to people in different parts of the world who are entrepreneurs, purchasing managers, key opinion leaders and knowledgeable clinicians.

Prior to joining MD Start, Marion was the head of operations of Cardiologs Technologies, a French medtech start-up that uses artificial intelligence and cloud technology to provide advanced screening for atrial fibrillation and other heart rhythm disorders. Philips agreed in November 2021 to buy Cardiologs.

Marion holds a Bachelor in Biomedical Science from Imperial College London, and a Master’s in Management (major in Entrepreneurship) from HEC Paris.

Fernando is an Investment Director at Endeavour Vision focused on medical technology, digital health and diagnostics investments, with a particular focus on orthopaedics, robotics, dental, ophthalmology, ENT and GI. Since joining the firm, he has undertaken multiple sector reviews, led deal screening efforts and participated in and directed a number of due diligence projects. Fernando represents Endeavour Vision as a board member for Miach Orthopaedics and Virtual Incision Corporation, and has previously represented Endeavour Vision as a board observer for SOPHiA GENETICS (NASDAQ:SOPH) prior to the company’s IPO in July 2021. He was on deal teams for investments in Miach Orthopaedics, Virtual Incision Corporation, InBrace, Lumeon, SOPHiA GENETICS and CeQur.

Prior to joining Endeavour Vision Fernando was an Engagement Manager at McKinsey & Company. There, he led numerous business strategy and organisational projects including therapeutic-area strategy, merger management, process optimisation, operating model re-design, corporate due-diligence and market access and launch preparation. Fernando worked across multiple geographies, including Switzerland, France, Germany, Belgium, UK, US and Brazil and sectors such as diabetes, specialty pharmaceuticals, infectious disease, wound care, surgical instruments, orthopedics and dental. Before McKinsey, Fernando led the development of several orthopaedic trauma solutions at Stryker Orthopaedics R&D in Switzerland – focusing on upper trauma and extremities.

Fernando holds an MEng degree in Biomedical and Mechanical Engineering from Imperial College London and the Swiss Federal Institute of Technology (ETH) Zürich. His Masters’ thesis was in cardiovascular fluid mechanics of stented arteries.

20+ years of research, business development, strategic partnerships and venture investing experience to development of new medicines and emerging healthcare technologies. Track record of advancing and investing in innovative technologies at public and private companies. Well established extensive global network across academia, biotechnology, pharmaceutical, foundations and investors. Career contributions include FDA drug approvals and marketed products, company acquisitions and IPOs.

Dr. Sascha Berger is a Partner at TVM Capital, based in Munich, Germany. TVM Capital is one of the transatlantic Life Science Venture Capital pioneers, investing with teams in Europe and North America. Sascha joined TVM Capital in 2016, helped to raise the current $480M fund, and works closely with entrepreneurs and founders to advance promising pharmaceutical assets, medtech, diagnostic, and digital health technologies to the next value inflection points. Sascha is a passionate VC, a Boston Consulting Group alumnus, and has an academic background in chemistry and finance.

Over the past 10 years, I have led commercial efforts for disruptive technologies in the digital health, wearables, and cardiac remote patient monitoring industries, playing a significant role in building the teams and cultures for 3 of the top 4 market share players, including #1 (BioTelemetry), #2 (iRhythm), and #4 (Bardy Diagnostics).

Overall, I’m a 20 year digital health, medical device, and remote monitoring innovator with successful senior leadership experience ranging from a Fortune 500 company (Boston Scientific) to a medium sized #1 market share (Biotelemetry, acquisition by Philips for $2.8 Billion in December '20) to 3 start-ups, 1 of which eventually led to an extremely successful IPO (iRhythm) and another which was acquired by HillRom (Bardy Diagnostics) in August '21 for what will end up being $400M+ after milestone payments.

Along the way I accomplished the following achievements most recently:

• Built the teams, culture, and infrastructure, as well as developed the strategies and executed on the business plans to help drive global commercialization efforts of a disruptive cardiac monitoring patch (CAM Patch), resulting in multiple rounds of venture capital, including a $35M+ round in April 2019.
• Raised significant shareholder value as well as a combined $100M+ in venture capital funding for iRhythm and Bardy Diagnostics, leading successful commercialization efforts for both by focusing on recruiting the right people, building the right culture, and developing strategic plans that led to explosive growth.
• Led Biotelemetry to profitability for the first time ever, and grew them to the #1 market share player, in part by developing a winning team and culture to successfully grow revenue for 18 consecutive quarters from $111M in revenue in 2012 to $208M in revenue in 2016, exceeding quota in all 18 quarters.
• Drove successful acquisitions of competitors and emerging technology, as well as developed impactful strategic partnerships, all of which added to the explosive growth of these companies.

Specialties: Sales and marketing leadership and management, building winning teams and cultures, commercialization and scaling of start-ups, venture capital fundraising, business planning, medical device sales, disruptive new product launches, Cardiology and Electrophysiology implantables and diagnostics, National Accounts, market development, marketing, recruiting and hiring sales talent, people development, contracting (negotiating and deal structuring), finance, strategic operations, strategic pricing, budgeting, and forecasting.

Responsible for managing existing IGT investment portfolio, including board of director seats, and for executing new investments in collaboration with IGT business development colleagues.

Specialties:
• Venture Capital investing focused on medical devices
• Business/Corporate Development (mergers and acquisitions, investments, partnerships) - due diligence, financial analysis, negotiations, integration planning
• Strategy and Portfolio Management
• Product Development Marketing

Mr. Josh Berg is an experienced healthcare investment professional with over 26 years of capital markets, investment banking, institutional investor relations and investment management expertise. Mr. Berg is well-versed and skilled at identifying value at all stages of a corporate life cycle and specializes in strategically building institutional shareholder bases for multinational organizations. Mr. Berg’s institutional investor relationships collectively manage more than $300 billion in equity value. Prior to founding Berg Capital Markets, LLC, Mr. Berg developed expertise in institutional equities with bulge bracket and boutique healthcare centric investment banks including Leerink Partners, Wells Fargo Securities, and Pacific Growth Equities. Previous to Mr. Berg’s 11 years of investment banking experience, he facilitated the raise of over $2.0 billion in equity securities for Jurika & Voyles, LP, a value-based institutional equity investment management firm based in Oakland, California.

Through Berg Capital Markets, Mr. Berg and his colleagues successfully deliver a robust, full-service capital markets solution for both public and private Healthcare and Energy companies.
Mr. Berg graduated with a Bachelor of Arts degree in Economics from the University of California at Santa Cruz. Mr. Berg currently lives in San Diego, California, and enjoys reading, traveling, working, cooking, working out, running, investing, and spending time with his children.

30 years experience in M&A, partnering, private and public fund raising and strategic planning in the industry and as an investment banker + Board directorships in France and Germany. Experience in big pharma, mid-pharma, biotech, medtech and CRO, and in investment banking in Europe, in the US and in emerging markets, with a large number of transactions closed.

Martin Chamberlin is a Managing Director in the European Healthcare Investment Banking team at RBC Capital Markets.  Martin advises public and private clients on a broad range of investment banking products including debt, equity and M&A.  He focuses upon the healthcare services and medtech sectors and works with clients across a wide range of sub-sectors including clinics and care facilities.  The global RBC Capital Markets Healthcare team also has members in North America and Asia and Martin works closely with these colleagues.

Estelle is a SeniorAssociate in SpeedInvest's Health Team and looking for exciting companies in the Digital Health space. 

Prior to joining SpeedInvest, Estelle worked at Inkef, a VC-fund specialized in Technology and Healthcare. During her time there, she re-designed the investment thesis in Digital Health with a sector-focused approach involving both teams. Before entering the VC world, she co-founded a start-up called Nanoshield developing nanomaterials for medical devices. Estelle completed her Master’s degree in Biotechnology at Imperial College London and her Bachelor’s in Biomedical Sciences at McGill University. 

Outside of work, Estelle is a songwriter, piano composer and sings in a Funk & Disco band. From time to time, you can stumble across her band in a small bar or stage somewhere in Paris…

Joël oversees all operations at Ysios Capital, including management, strategy and day-to-day operations.

Previously, in 2001, Joël co-founded Glycart Biotechnology and was its CEO until its sale to F. Hoffmann La-Roche four years later. Glycart Biotechnology was the originator of the anti-CD20 antibody – obinituzumab/Gazyva® – the first breakthrough designated drug approved by the FDA in 2013.

Joël was elected one of the 50 key players in biotechnology in Switzerland in 2003 and earned several innovation awards for Glycart Biotechnology, including the Wall Street Journal Europe Innovation Award in 2001.

Joël holds a MSc in Biotechnology and a PhD in the fields of Cell Biology and Immunotherapeutics, both from the Swiss Federal Institute of Technology (ETH Zürich).

Hussein is a partner at Hoxton Ventures. He currently represents Hoxton on the boards of Avantia Law, Baseimmune, BeyondRisk, Biocortex, Biotx, DruidAI, Finesse, Fy!, Giraffe360, Kbox, Kitt, Luminary, Peptone, PillSorted, Raptor Supplies, Really Clever, Rensair, Replai, Replan, Skin Analytics, TourRadar and XYZ Reality, and serves as a board observer on Behavox and Karakuri. He previously served on the boards of Babylon Health (NYSE:BBLN), bd4travel (acquired by Dnata), Campanja (acquired by 24/7 Media), Darktrace (LSE:DARK), Deliveroo (LSE:ROO), Panakeia, SOCOS (acquired by Sophos), Yieldify (acquired by Publicis) and Vidya Health. 

Hussein serves on the board of UCLB, the commercialization company of UCL and also sits on the advisory board of GTO Partners, a tech mid-market buyout firm, and Landscape, a venture capital review site. Previously he served on the board of Tech Nation, a UK quasi non-governmental organization. In a personal capacity, he is an angel investor in Apex:E3, Builder.ai, Callaly, GoCardless, Mellizyme, MyGlamm, Reachdesk and Signpost. 

While forming Hoxton, he helped Eros STX Global develop ErosNow, an online streaming video platform for Bollywood. Prior to Hoxton, Hussein was an associate with Accel Partners. He joined Accel from Microsoft Corporation. Earlier in his career, he worked with three startups, Safe-View (acquired by L-3), Radiance Technologies (acquired by Comcast) and Studio Verso (acquired by KPMG). 

Hussein holds an MBA from London Business School and did his undergraduate studies in Symbolic Systems at Stanford University.

Yassaman is a partner in the Healthcare Investment Banking Group and runs the medical device coverage effort. She served as the group's business unit manager in 2008. Yassaman is co-head of the Georgetown University undergraduate and MBA recruiting efforts for the Investment Banking Division. She joined Goldman Sachs in 2005 as an associate and was named managing director in 2013 and partner in 2020.

Prior to joining the firm, Yassaman worked in the Investment Banking Division of Morgan Stanley and in the Corporate Development group at Avaya. Yassaman earned a BS in Foreign Service and an MBA, both from Georgetown University.

Bio coming soon.

Former startup founder and biomedical engineer turned VC. Investing in early stage Health Tech across EU, UK, US, CA, and IL.

Dr. Martin Gershon is Managing Partner & CIO of Endeavor Venture Funds & Venture Studio.

Over the past 23 years Dr. Gershon raised over $1B, is a prominent Investor & entrepreneur, featured on CNBC, personally started & exited 6 startups, has expanded & developed an ecosystem of collaboration partners within Big Tech, Digital Healthcare, Pharma, Biotech, Medtech, world class accelerators Techstars, Plug&Play, MassChallenge, & prominent Ivy League universities & business schools Harvard, Columbia, NYU, leveraging core competencies of the partnerships.

Endeavor Venture Fund is an evergreen Swiss Healthcare and Life Sciences Fund, established in 2009. Endeavor’s companies possess disruptive technologies with strong scalable commercial potential, driven by great entrepreneur/founders who look for coaching & partnerships within our ecosystem to enhance and build their companies into the next great unicorn.

Endeavor Venture Fund I invested in groundbreaking biotech companies like Moderna & 69 life science companies with 55 exits.

Endeavor Venture Fund II & Endeavor Venture Studio-The Alternative to Accelerators-was established June 2022. Unlike an accelerator, the Venture Studio doesn’t fund existing startups. Instead it provides weekly “hands on” guidance & operational & strategic support in an ecosystem of seasoned entrepreneurs, subject matter experts & business leaders dedicated to help grow, scale & commercialize the company’s products over a 4 year period. The most famous venture studio alum Is Moderna.

Endeavor II & Venture Studio particularly target emerging Digital Healthcare Unicorns to develop partnerships to expand AI Healthcare use cases in collaboration with BigTech & Cloud Providers, providing companies with bespoke growth strategies that accelerate commercialization & generate new stand alone revenue streams.

As the Managing Director of Endeavor Dr. Gershon is the architect driving a team of 22 professionals to leverage Endeavor’s ecosystem of collaboration partnerships to provide CEO/Entrepreneurs with bespoke revenue generating Go-to-Market strategies, FDA regulatory services, clinical trial design, reimbursement & coding guidance, and the development of strategic & financial corporate partnerships to grow, scale, & commercialize disruptive new healthcare products & services stemming from technologies like AI and ML.

Dr. Gershon is a designated S&P Healthcare Industry Leader, contributing author Fast Company, Memorial Sloan-Kettering Cancer Center Mayday Fellow neuroscientist, oncologist/immunologist, former FDA attorney.

Bio coming soon.

15+ years experience in investment, marketing, strategy, business development and entrepreneurship in the Life Science and Med Tech industry, in senior roles. Master of Science in Molecular Biology and a degree in Marketing and Business Administration from Entreprenörskolan, Uppsala University.

Chief Operating Officer of Santé Accel, a Santé affiliated company focused on creating and fostering the development of seed stage opportunities as well as a network of entrepreneurial talent. Through incubation, company formation, talent matching, and extensive coaching, I help these medtech, biotech, and healthtech companies grow and prepare for larger investment from Santé’s main investment funds.

Dr. Kolo has spent her career working at the intersection of finance and technology, previously as a Director at a global investment bank, a Partner in one of the world’s largest law firms, and as an entrepreneurial executive. Deep expertise in capital raises, mergers and acquisitions, investment in technology and intellectual property, and structuring transactions, with focus on medical device and cyber.

Inspiring Leader & Bridge Builder, combining innovation successes in Healthcare and Technology Business with a passion for transforming ideas into reality - in early-stage ventures and mature businesses.

Sayan joined J.P. Morgan’s healthcare investment banking division in 2022 focusing on advising clients in the MedTech space across Europe.

Prior to this, he was a Vice President in the healthcare investment banking team at Goldman Sachs where he spent almost a decade, across two stints, advising clients in Europe, Middle East and Africa. In between his two stints at Goldman Sachs, he was helping create the healthcare private equity business for Ashmore focused on emerging markets.

Sayan has a masters degree in Economics from the Delhi School of Economics and a bachelors degree with first class honours from Presidency College, Kolkata.

Ken Ho is Investment Associate at LifeArc Ventures, responsible for new investment opportunities with a particular focus on healthtech.

Ken has eight years’ experience in ventures and venture capital in strategic and financial analytics roles. Prior to joining LifeArc, Ken was Senior Financial Analyst at Arts Alliance Ventures, looking across an industry agnostic, tech-enabled ventures portfolio.

With a master’s degree in physics from Oxford University, Ken takes a keen interest in world-positive innovations, engineering, and fitness.

Kreos has committed more than €3 billion in over 600 portfolio company transactions across Europe and Israel.

Entrepreneurial investor with experience in: Growth Capital, Venture Capital, Corporate Venturing, Entrepreneurship, General Management, Strategic Marketing, Strategy, Business Development, Innovation Management, Research & Development; in the following Industries: Medical Devices, MedTech, (In vivo, In vitro, Molecular, Companion) Diagnostics, Digital Health(care), Healthcare IT, Consumer Health, High Tech, CleanTech / Renewable Energy

Dr. Marengère is responsible for TVM Capital Life Science’s overall investment strategy and global fund operations.

Dr. Marengère joined TVM in 2012 and has 23 years of venture capital experience. He was a key driver of the implementation of the TVM LSI I investment strategy which resulted in a number of investments. He is a Director on the Boards of Emovi Inc.; Acanthas Pharma; Occelaris Pharma; Ixchelsis; PRCL Pharma; Panthera Dental; FAAH Pharma; Kaneq Biosciences; Acer Therapeutics as well as Rapid Micro Biosciences. Luc was on the Board of Colucid Pharma Inc. and Aurka Pharma which were recently sold to Eli Lilly for US $960M and US $575M respectively.

Dr. Marengère brings a significant track record to TVM given his long standing experience as  a Venture Capitalist. Very notable deals during Luc‘s previous tenure as Managing Partner at VG Partners include Cytochroma Inc. (sold to Opko for US$ 400M); VisualSonics (sold to Sonosite for US $75M) and CITA Neuropharma (sold to Vernalis Plc for US$ 85M). Prior to joining VG Partners, Luc focused on making venture investments in the life science sector while at La Caisse De Depot‘s venture capital group SOFINOV as well as MDS Capital and MedTech Partners.

Prior to his venture capital career, he conducted commercially-oriented research in the fields of immunology and oncology while at Amgen. Luc holds a Ph.D. from University of Toronto‘s department of Medical Biophysics and Molecular Genetics.

Since 2016, I have led fundraising and closing on over $100M of seed/early stage Medtech deals resulting in the formation and development of seven new companies.

I joined the Coridea team in 2014 and currently function as the Chief Business Officer of Deerfield Catalyst, an incubator partnership between Coridea and Deerfield Management. My current responsibilities include innovation management, managing all financial aspects of the incubator and its portfolio companies, and business development.

Prior to my career in healthcare, I attended the Berklee College of Music and continued my journey producing music and developing artists through my production company that I began at age 16. During this period of time I also pioneered music technology programs in public schools throughout New York City and founded a travel consulting company to assist clients in acquiring and maximizing credit card points and miles. I am a board member of the Bronx Arts Ensemble, where I sit on the education committee.

Howard Levin, M.D., a heart failure transplant cardiologist by training, is an expert in creating novel therapies for cardiac, respiratory, neuro, and renal patients.

Scott is a successful Medtech CEO, Chairperson, board member, entrepreneur, and investor, having been involved in one of those roles in 20+ startup, growth and public companies with market valuations that have totaled over $20b and more importantly over 20 million patients that have benefited from the therapies & diagnostics of these companies, including 8 IPOs. Current professional affiliations include Principal Front Foot Ventures, Executive Chairperson Hyperfine (HYPR) IPO 2021, Chairperson Acutus Medical (AFIB) IPO 2020, Chairperson Envista (NVST) IPO 2019, Board Member Nuvasive (NUVA), Exec Chairperson & Invester Elucid, Exec Chairperson & Investor Wondr Medical, Chairperson of the Board & Investor Kardion, Board member & Investor, Q’apel Medical, Board member & Investor Proximie, Board member & Investor Foldax, Board Member Veranex Solutions, Advisor & Investor Genesis Healthcare, Advisor & Investor Cortica, advisor Brightinsight, Board Member & past Chairperson Medical Device Manufacturer’s Association (MDMA), and advisor to Peloton Equity, 8VC, River Cities Capital and Accelmed Equity. He completed his role as Pres & CEO of Verb Surgical in early 2019. Verb was Google & J&J’s Surgical Robotics and Digital Surgery platform start-up to revolutionize the future of surgery which J&J acquired in 2019. Previously, Scott led Volcano Corp. (VOLC), a leader in minimally invasive therapy guidance in interventional cardiology, as its first & only Pres & CEO, from start-up in 2002 to its IPO in 2006 and sale to Philips in 2015. Volcano 2014 revenue was > $400 million and its market capitalization peaked at nearly $2B. Prior to this, he was at Digirad Corp, a coronary imaging solutions provider, from 1997 to 2002, as President & CEO. Digirad went public in 2004 (DRAD). He graduated Magna Cum Laude with a BS in Bus Admin from the Univ. of Southern California in 1986 and earned his MBA from the Harvard Business School in 1991. Past affiliations include 12 other public and or VC funded medtech and biotech company boards of which 9 have had significant exits, including Chairperson of Endochoice (GI, IPO 2015, acquired by Boston Scientific), Chairperson Sonendo (SONX IPO 2021), board member Vicarious Surgical (RBOT IPO 2021), board/CEO advisor Digital Surgery/Touch Surgery (Acquired by Medtronic). Scott has also been awarded E&Y’s entrepreneur of the year award in 2010 & was recognized by Goldman Sachs in 2016, 2017, & 2018 as one of the 100 most intriguing entrepreneurs at its annual Builders & Innovators conference.

Kwame Ulmer is a venture partner at Wavemaker Three-Sixty Health - the leading Southern-California based, early stage venture capital firm (Seed and Series A) focused on the healthcare industry. He leads the medtech practice and participates in all aspects of fund management (e.g. deal sourcing, diligence, negotiation and advising portfolio company management teams).

Kwame brings twenty years of experience evaluating medical technologies in the government and private sector, and serving in senior operating roles at medical device companies. He has personally evaluated more than 1,000 medical technologies in his career. Kwame spent 12 years at the U.S. Food and Drug Administration (FDA) in progressive leadership roles, including Deputy Director and Branch Chief. He also served as Vice President, Regulatory Affairs and Quality Assurance at Implant Direct, a Danaher Corporation operating company.

Kwame serves on the board of the University of Virginia Licensing and Ventures Group and the California Life Sciences. He is also a lecturer and researcher in MedTech Innovation at the University of California, Los Angeles. Kwame founded MedTech Color, a nonprofit with a mission to advance the representation of persons of color in the medical device industry. He earned his B.S. in Physics from Lincoln University, and has two Masters degrees from the University of Virginia, in Materials Engineering and Business Administration.

Raised in the melting pot of the Bay Area before attending USC to major in biomedical engineering, Tracy took to heart Theodore von Kármán’s famous quote: “Scientists discover the world that exists; engineers create the world that never was.”  In pursuit of creating a better world, she headed to medical school at Stanford where she quickly experienced firsthand the challenges of getting innovative products into the hands of clinicians to ultimately improve patient care.  

Pivoting to industry, Tracy spent several years in healthcare M&A, then moved to Novartis Diagnostics, where she worked with Linda.  As Chief of Staff to the President, she led strategy and built out the innovation pipeline, then headed global operations. More recently Tracy has been focused in digital health, where she advised a range of organizations, from early-stage startups to the Novartis Digital Accelerator Lab and the Bill and Melinda Gates Foundation, before joining Avestria. She is also a member of the Women’s Health Executive Committee at Springboard Enterprises.

A classically trained violinist, Tracy believes that art & creativity is a critical underpinning for “STEAM” education.  She’s a fan of swimming, baking, and impromptu dance parties with her daughter.

I co-founded and manage a new VC firm, Panakès Partners, a Venture Capital firm, based in Milan, which invests in the most ambitious companies and teams, developing revolutionary technologies and products, in the field of life sciences, aiming to improve the lives of people around the world. Panakès has 250 million under management, in two funds.

I have 9 years VC experience in Sofinnova, one of the largest European VCs, grown internally from Analyst to Partner positions, with European and American exposure, focused in energy, IoT, cleantech, hardware and semiconductor sectors.

I am a creative, dynamic and hard worker, able to create business opportunities for the invested companies with his strong network at executive level and for the firm with his strong network of entrepreneurs, VCs, labs, intermediaries.

Josh Makower is a Special Partner on NEA's healthcare team. Josh is also the Founder and Executive Chairman of ExploraMed.

Notable transactions from the ExploraMed portfolio include NeoTract, acquired by Teleflex in 2017, Nuelle, acquired by Aytu in 2017, Acclarent, acquired by J&J in 2010, EndoMatrix, acquired by C.R. Bard in 1997 and TransVascular, acquired by Medtronic in 2003. On-going ExploraMed ventures include Moximed, Willow, Revelle Aesthetics and ExploraMed V.

In addition to his role at NEA, Josh serves on the faculty of the Stanford University Medical School as a Professor of Medicine and Bioengineering and is Director and Co-Founder of The Stanford Byers Center for Biodesign. Josh currently serves on the board of directors for DOTS Devices, Eargo, ExploraMed, Intrinsic Therapeutics, Moximed, Willow, SetPoint Medical and Coravin.

Josh holds over 300 patents and patent applications for various medical devices in the fields of cardiology, ENT, general surgery, drug delivery, obesity, orthopedics, women’s health, and urology. He received an MBA from Columbia University, an MD from the NYU School of Medicine, and a bachelor's degree in Mechanical Engineering from MIT.

Maria Berkman, MD, MBA, is the Head of the MedTech practice at Broadview Ventures where she manages the firm’s MedTech investment strategy and activity, from identification and screening of new opportunities through diligence, deal structure and syndication, portfolio company board management, and overarching portfolio strategy.

Maria is also the Managing Director of Longview Ventures, an independent investment vehicle focused on clinical-stage opportunities, as a complement to Broadview’s dedication to Seed and Series A financings.

Maria currently serves on the boards of Alleviant Medical, Aria CV, AtaCor, FineHeart, RapidPulse, Vascular Graft Solutions, and Vectorious Medical Technologies, and previously served on the boards of Lyra Therapeutics (NSDQ:LYRA), Apama Medical (acquired), Remedy Therapeutics (acquired), and Capricor (NSDQ:CAPR).

Prior to joining Broadview Ventures, Maria was a management consultant at Monitor Group, and trained at Mass General Brigham’s Newton Wellesley Hospital. Maria earned a concurrent MD from the UCLA School of Medicine and MBA from the Anderson School of Management at UCLA, graduating Alpha Omega Alpha.

Outside of Broadview, Maria serves as a member of the Board of Advisors at the Boston Museum of Science, member of the AdvaMed Investor Working Group, and Co-Chair of the NEVCA MedTech Academy; Maria previously served as a VC Mentor for the UCLA Biodesign Fellowship, SBIR/STTR grant reviewer for the National Science Foundation and as a Strategic Advisory Board Member for the RAD BioMed Accelerator in Tel Aviv, Israel.

Mr. Assaf Barnea is a seasoned entrepreneur and venture professional, with extensive, multidisciplinary
experience in building innovation platforms and leading investments & commercialization processes in healthcare and life science related technologies. He leads, since its inception in 2014, Sanara Ventures, a healthcare innovation fund, backed by Phillips and Teva investing in digital health, medical devices & Bio-Convergence technologies. He is also the Founder & Managing Partner of Sanara Capital, a follow up fund of Sanara Ventures, that focuses on A&B rounds investments in healthcare related technologies.
Parallel to his role at Sanara, Mr. Barnea Chairs also the Life Science Advisory Board at the Israel Export Institute, on behalf of the Israeli government, promoting and advancing the export of Israeli technologies in the medical, biotech, pharma and digital fields in global markets. Previously, Mr. Barnea was also advising the World Bank’s IFC venture capital team and is a co-founder of the IFC’s Tech Emerge program; a unique acceleration platform that connects healthcare startups from around the world with leading corporations and hospitals in emerging economies. In 2018, Tech Emerge Health has won the world bank group president’s award for innovation.
For over a decade, Mr. Barnea was a BOD & co-founder of CardioSense, a medtech startup company.
Assaf served as CEO of Kinrot Ventures, spearheading its acquisition by Hutchison Water in 2012. Prior to this, he headed business development at Mekorot, Israel’s national water company, where he oversaw the establishment of WaTech, the Entrepreneurship & Partnership Center for Water Technologies. For his role and accomplishments in both Mekorot and Kinrot, he received the Cleantech Group’s Innovation Hero Award in 2013 (see video below).

Previously, Mr. Barnea served as a director of business development at Comverse, where he also co-chaired the Mobile Marketing Association.
A unique highlight in Assaf’s story is his former stint as a college basketball player at New Jersey’s Seton Hall University, where he won the Big East championship against Georgetown in 1991. Assaf holds LLB and Business degrees from the Interdisciplinary Center in Herzelia, a BA in political science and psychology (with honor) from Tel-Aviv University.

Nicole is a Healthcare Innovator & Connector, Board Director, Family-Senior Care advocate, and a former Managing Partner with Arboretum Ventures, Baird Capital, Abbott Biotech Ventures.

Originally trained as an engineer at Stanford University, Nicole has a career evenly weighted between operating roles and venture investing. She started her career with ACS/Guidant as a process development intern and advanced through multiple R&D and management roles until her final position as Head of Marketing, Asia-Pac, based in Hong Kong. Then moving onto Abbott, Nicole led strategic market activities for Abbott’s OUS discrete glucose monitoring and continuous glucose monitoring brands, with a final role as the Founding Director of the Abbott Biotech Ventures team.

Nicole is passionate about healthtech investing and working with entrepreneurs to transform the delivery of healthcare by focusing on innovations at the intersection of biology & technology.

Imran is a biotech and healthtech venture capital investor at LifeArc Ventures. He is responsible for both leading new investments and managing existing portfolio companies.

Imran is a former surgeon, digital health entrepreneur, and corporate development professional. He has been integral to over $1.5bn venture, licensing, and M&A deals at digital health, med tech and biopharma companies.

Imran received his medical degree from Imperial College London, where he graduated with joint honours from the Imperial College Business School and is a member of the Royal College of Surgeons.

He is committed to using his experiences to advance innovation to support the delivery of higher quality care and improve clinical outcomes.

Lu Zhang, Founder and Managing Partner of Fusion Fund, is a renowned Silicon Valley investor, a serial entrepreneur, and a Stanford Engineering alumna. Lu is a World Economic Forum - Young Global Leader. She has also garnered other accolades including the Featured Honoree in VC of Forbes 30 Under 30, Silicon Valley Women of Influence, Town & Country 50 Modern Swans – Entrepreneurship Influencer, and was recently selected as the Best 25 Female early-stage Investor by Business Insider (2021). Prior to starting Fusion Fund, she was the Founder and CEO of a medical device company (acquired in 2013). Lu is a frequent speaker at tech events and conferences such as Davos World Economic Forum, Future Investment Initiative (FII), Forbes, Web Summit, SuperReturn, etc., and serves as a mentor and advisor to several tech innovation programs in Silicon Valley. Lu is the board member of the Youth Council of Future Forum and Future Science Award. Lu is also on the Jury Board of Cartier’s Young Leader Award. She received her M.S. in Materials Science and Engineering from Stanford University.

Debra Netschert is a portfolio manager for Jennison’s healthcare strategies. She is responsible for overseeing the investment process, strategy implementation, and risk management for all healthcare strategies. Before joining Jennison in 2008, she was with Magnetar Capital as a senior analyst specializing in health care. Prior to that, she worked at Amaranth Advisors focusing on biopharmaceuticals and at Lazard Capital Markets covering biotechnology. Debra began her research career as an associate biotechnology analyst at UBS. She received a BS in health science and MS in physical therapy from Boston University.

John leads the healthcare division of WFSC which is focused on direct equity and debt investments in companies across all subsectors of the healthcare industry. John has been a venture capital and private equity investor for more than 24 years and has participated in the founding, building, and financing of companies, ranging from startups to established industry leaders in a wide array of healthcare sectors. John started his career as an investment banker covering the healthcare industry.  John earned a BS with high honors from the University of Colorado at Colorado Springs and an MBA from Harvard Business School.  John is based in San Francisco, California.

Rana Lonnen is a healthcare technology investor, entrepreneur, and molecular biologist. At Novartis, she leads strategic investments in technology companies, on a mission to transform the healthcare ecosystem and make positive impact on people’s lives.

Previously, Rana was Head of Preclinical Development at a UK biotech, Auspherix; investment consultant to IP Group in London; Founder and CSO of a UK based Biotech, Axendos therapeutics. Prior to this she was a Wellcome Trust backed principal investigator in drug discovery in the field of Infection, Immunity and Inflammation, author and inventor on high impact peer-reviewed publications and patents; before this, Rana worked at Bristol-Myers Squibb, in sales and marketing.

Rana holds a PhD in molecular biology and an MBA from Imperial College London. She personally cares about equitable healthcare, social justice, sustainability and the future of antimicrobial resistance. In her down time Rana likes to make culinary experiments, be in nature and read.

Rana is a board observer at Aktana, Cota Healthcare, H1 Insights, Koneksa, Mekonos, NuvoAir, and Dopavision. She is based out of Basel, Switzerland.

What drives me? - Innovation, curiosity and the conviction that your mind is your most powerful tool.

What interests me? - I would say many things. However, if you would restrict me to one topic, I would always choose Biomedicine. Biology is a mindblowing technology and we are only starting to realize its full potential. Medicine is the beginning of this journey and my personal starting point.

Who I am? - I am person who needs challenges. As a strategy consultant I am faced with new challenges on every project and they empower me. Also, I like working in teams. The best ideas and solutions are developed during a discussion. I love to work with people who manage to challenge and support you at the same time.

With over a decade of experience working in the medical device and diagnostics industry, I've worked across a range of organizations and geographies to achieve my position as the Vice President of Strategic Development for Diagnostics at Hologic.

From starting as a sales representative to becoming a VP, I've progressed in leading organizations across North & South America, EMEA and APAC by learning new skills from a range of colleagues and global experiences over my 17+ year career and by believing that I will never stop learning.

Eric Schantz is a Vice President of Corporate Development at Medtronic, currently focused on mergers and acquisitions in the cardiovascular portfolio, along with other strategic corporate transactions. Eric joined Medtronic in 2008 following several years as a sell-side equity research analyst covering numerous segments in medical technology including cardiovascular, orthopedics, ophthalmology, aesthetics, neuromodulation, and the insurance providers. Eric received a BS and MS in engineering from the University of Cincinnati, and an MBA from the University of Texas at Austin.

Global strategic leadership within the health care and MedTech industries with a focus on delivering innovative business models, software and solutions that advance patient care & drive profitable growth.

Bio coming soon.

Ehsan is an academic entrepreneur turned investor. A Ph.D. graduate from Drexel University’s Chemical and Biological Engineering, he stumbled into entrepreneurship during his postdoc at the California Institute of Technology. Upon starting his career at the University of South Carolina as a Professor, he led his lab to focus on translational research in biomedical engineering. He concurrently pursued an MBA in Finance and Entrepreneurship at the University of Southern California, Marshall School of Business, to strengthen his business acumen. Ehsan was the Founder and CEO of Obsidio Inc, a venture-backed medical device company dedicated to developing innovative technologies for interventional medicine. Obsidio was launched in 2019 and acquired by Boston Scientific in 2022.

Julien Michaux joined Norgine Ventures from Lazard where as a member of the Healthcare M&A team he advised many European and US clients on merger and acquisition transactions. Julien joined Lazard in 2005 from J&J Pharmaceuticals where he worked as part of the M&A team. Julien has 19 years of experience in the Healthcare industry. He started his career with Procter & Gamble.

Julien holds an MS in Mechanical Engineering from ICAM in France and an MBA from the Anderson School at UCLA.

Tim joined BGF in January 2018 after actively supporting BGF on a number of projects over the previous 18 months. He is based in London and Cambridge and his main role is to identify and execute investments with a particular focus on tech-oriented propositions.

He also takes a lead role in developing relationships with partners that can help BGF better support key industry sectors. Tim has been active in the venture capital and start-up ecosystem for over 20 years, initially as an entrepreneur and then as an investor with SoftBank, NEC and DFJ ePlanet Capital. He has been a party to more than 120 investments across a broad range of sectors, stages and geographies. He has recently joined the BGF Investment Committee.

Outside of work Tim spends as much of his time as possible on horseback and, in the interest of combining work with pleasure, keeps a horse specifically for long conference calls. Tim has a science background and began his career in BT’s research labs developing materials for optical switching and amplification. He has an MBA from London Business School.

Seasoned, results-driven leader experienced in identifying, launching, spinning-out, funding, building, scaling, and turning-around opportunities in healthcare and technology; strategy; operations; partnering; commercialization; and exits. Experience from roles including founder, VC, CEO, Board Chair, counsel, and advisor. Specialized in start-ups; enterprise incubation/creation; venture finance; developing/supporting early-stage and growth-stage ventures; turnarounds; and special opportunities.

Venture Capital/Private Equity: Knowledge from all sides of the table: generating/evaluating deal-flow; investing; building/managing companies/portfolios; structuring, positioning, leading, and executing financing, strategic, and exit transactions.

Leadership: Strategic planning/implementation, financial management, organizational/team development, mentoring, creating/aligning incentives, IP strategy, regulatory strategy, reimbursement, compliance, risk management, partnering, and structuring/executing financing, strategic, and exit transactions.

Technologies/Services: Domain expertise identifying, developing, financing, and commercializing healthcare, biomedical, IT, and convergence technologies; developing, implementing, and managing concepts, structures, programs, and alliances for healthcare delivery, management, infrastructure, service, support, and payment, including population health, ACOs, global risk, and MSOs.

Board Experience: Healthcare, technology, and other areas. Lead/mentor management/boards to develop/implement structure, process, and culture for teamwork, transparency, accountability, and performance.

Innovation, licensing and partnering professional with a specialised background in oncology and neuroscience. Ph.D. in Neurobiology. Extensive expertise in the field of cancer stem cells (CSC) and immuno-oncology, CNS and neural stem cells.

Epidarex is a transatlantic venture capital firm led by a diverse team of early-stage investors building breakthrough life science companies in emerging hubs.

Samuel is a physician entrepreneur.

He started his career as a management consultant at McKinsey & Company in New York before moving to Boston to attend Harvard Medical School. As a second-year medical student, Samuel co-founded Allurion Technologies and built a fully-integrated, global medical device company from the idea stage to commercialization in more than 30 countries.

Samuel is a graduate of Yale College (summa cum laude) and Harvard Medical School. He was a Fulbright Scholar to France at the Pasteur Institute.

Gal previously co-founded and served as CEO of NeuroLabs AI, an opioids dependence prevention platform, tackling the opioid epidemic through ongoing assessment of pain and mood symptoms at home. Gal also previously served as VP Business Development and Director of Healthcare at a multinational AI expert firm, and as an investment analyst at aMoon, the largest venture capital fund in Israel. 

Gal holds a PhD in Clinical and NeuroPsychology in chronic pain (for which she was awarded the national Wolf Scholarship) and has frequently published in top tier medical journals such as Vaccine and Psychiatry.

Richard has worked across the innovation-to-business spectrum from biotechnology research to product development, marketing and commerce including company formation and leadership in both large and small organizations. Trained at Imperial College, London, his Ph.D. in microbial biochemistry was sponsored by the UK health service, where Richard worked as a senior scientist before transitioning to industry. He progressed to business and company development while maintaining technical leadership. He was a key member of the executive team that transformed Whatman plc, the UK industrial filtration company, into a global healthcare business that became GE Healthcare. During the last ten years he has worked for investors in diligence and turn-around roles, mostly in the United States. Richard provides pro-bona support to exciting start-ups, judges the annual international Katerva Innovation Awards and candidates for the MedTech Innovator program, and supports Level Eight investments as a board member or advisor. Away from business he loves sailing and intends to cross an ocean or two.

I am angel and venture capital investor who works with an internationally diverse network of accredited investors to create catalytic wealth through early stage investing. My venture advisory firm enables government agencies and large scale organizations to deploy global innovation initiatives that support science based startups and investors.

The Investors of Color (IoC) is a global network of diverse, accredited investors across the capital stack committed to building wealth for and by underrepresented communities through syndicated investments in early-stage companies.  The IoC is composed of over 800 investors representing the entire continuum of capital such as angel investors, ad-hoc investment networks, venture capital, revenue-based investment firms, family offices, and other capital providers.  The strength of IoC is a commitment to close the funding gap in startup capital.

The Trendlines Group is a leading Israeli investor in early stage companies.

Trendlines invents, discovers, invests in, and incubates innovation-based medical and agrifood technologies to fulfill its mission to improve the human condition.

Raf has a decade of operational experience in the biotech sector and holds an M.Sc. in Biochemistry and Biotechnology and an MBA from Vlerick Business School. Subsequently, he spent more than 5 years at Korys, focusing on life science investments. He was involved with several young innovative companies and served as a strategic advisor for European and US-based investment funds.

Principal at the Gimv Life Sciences team focusing on deal sourcing and execution to build & manage the Life Sciences portfolio of early stage companies. Currently on the BoD of Precirix and SynOx Therapeutics and part of the deal team of iSTAR Medical, FIRE1, ImCheck Therapeutics and Topas Therapeutics.

A personal background in (Epi)genetics, NGS and oncology combined with three years founding a Medtech start-up and two years in investment banking as a biotech/pharma equity research analyst.

Rob is a partner at Hoxton Ventures. He represents the firm on the boards of Assetario, Boost Security, Deblock, FabricNano, Flair Impact, Formance, Kheiron Medical, LiliumX, Limbo Revolution, NoMagic, Ordercast, Pear Bio, Phagos, Preply and Spacelift, and previously was on the boards of Babylon Health (NYSE:BBLN), Bother, Campanja (acquired by 24/7 Media), Immunio (acquired by Trend Micro) and Vatic Health. He additionally works on Hoxton's interests in Ochre Bio, Optimoroute and Verb (Poetics).

Having spent most of his career in Silicon Valley, Rob came to London in 2008 to join the investments team at Fidelity Ventures, focusing on consumer internet and software-as-a-service sectors.

Prior to Fidelity, he was on the new business development team at Google and was previously a lead product manager for AdSense's front-end systems. While at Google, he also launched the AdWords pay-per-action (PPA) product and was actively involved in the acquisition of Feedburner in 2008.

Rob began his career in Intel's highly selective technical sales program where he worked to grow their entrepreneurial reseller channel in the Federal Government vertical and later in Latin America from Bogota and Miami Beach.

A dual US/UK national, he holds a BS in Computer Science from the University of Maryland and a Masters certificate in Management Science & Engineering from Stanford University.

Currently diving into digital health as Investment Manager for Helsana HealthInvest, the CVC we've set up at Swiss health insurance Helsana. We're actively deploying in 2023, doing deals around Series A across Europe.

Sony Innovation Fund (SIF) is the venture capital arm of Sony Group Corporation and is dedicated to investing in and engaging with promising early-stage & growth-stage companies.

Headquartered in Singapore, CBC Group is Asia's largest healthcare-dedicated asset management firm, focused on platform-building, buyout, private credit, venture, and real estate, across the healthcare space, including pharmaceutical, biotech, medical technology, and healthcare services. We are committed to creating lasting value by integrating global innovations and talents. Partnering with the world's top entrepreneurs and scientists, our unique "investor-operator" approach has empowered leading healthcare companies to widen access to affordable medical care, catalyse innovations, and improve efficiency in fulfilling unmet medical needs worldwide.

Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. Gilde Healthcare's lower mid-market buy-out fund invests in profitable European healthcare services companies with a focus on the Netherlands, Belgium and Germany. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market. Gilde Healthcare's venture & growth capital fund invests in medtech, diagnostics, digital health and therapeutics. The portfolio companies are based in Europe and North America. Since 2001 Gilde Healthcare has raised €2.5 billion for its specialized funds.

• Aneta Sottil joined the management company in January 2018. She is Director within the Andera Life Sciences team, the team dedicated to life sciences and medical technologies.
• Aneta has 14 years of experience in life sciences issues, acquired in the field of M&A (BAML from 2006 to 2008; Rothschild from 2008 to 2013) and Venture Capital (Norgine Ventures from 2013 to 2018) .
• She graduated from Warsaw School of Economics, Singapore Management University and Pierre Mendès France University, in the field of Finance.
• A native Polish speaker, Aneta also speaks English, French and Spanish.

Bio coming soon.

Partner at Asabys, where he joined in 2018. Guillem is primarily responsible for sourcing, executing, and managing investments, with a major focus in the firm’s health-tech portfolio. He is also leading Asabys’ deal structuring, transactions and negotiations. Guillem currently serves on the board of directors of Amelia Virtual Care and Cara Care, and is an observer on the boards of Koa Health and Sidekick Health.

Prior to joining Asabys, Guillem was the Portfolio Manager of the Life Sciences portfolio at Caixa Capital Risc for four years. Before that, he served at EY within the Transaction Advisory Services primarily focusing on PE and VC transactions.

Guillem holds a BBA with a major in finance from Universitat Pompeu Fabra (UPF).

As a tech-enthusiast Lien is captivated by new ideas and innovations. Leveraging her deal making experience she will support imec.xpand's companies with the identification and set-up of impactful collaborations.

Bio coming soon.

Bio coming soon.

Since 2007, Medi-Vantage, a strategy consulting firm, has been dedicated to helping medtech, diagnostic, drug delivery & digital health companies disrupt markets, drive share and grow revenues by strategically outperforming their competition.

I build collaborative teams to perform medtech strategy research for our clients, and lead them to superior results.
- Accomplished business leader with a lengthy track record of success.
- Exceptional team builder and coach, with a reputation for finding and developing top talent.
- Strong and authentic communicator, at ease connecting with engineers, business leaders, analysts, investors, or customers.
- Deep expertise drawn from a career-long obsession with medical device product development and commercialization, and customer-centered design thinking.
- Adaptable and coachable. Always striving to learn and improve.

Our research generates strategic plans developed by subject matter experts and highly experienced medical device industry veterans.

Projects since 2007 have resulted in increased client revenues of greater than $1B; include market assessments/adjacent market entry decisions, commercialization plans, pricing strategy, investor pitch decks, five and ten year strategic plans, creation of sales and clinician training materials, VoC, human factors usability testing and market research for developing product and marketing requirement documents.

“We hired MV because a small medical device research firm has low overhead and cost. We hired them again because their work is exceptional, rich in clinical content and their understanding of the medical device industry is unrivaled.” – SVP Marketing, Cardiovascular Products

Born in Barcelona, I was raised in an entrepreneurial and international environment. The son of a Swiss mother and a Catalan father, I grew up watching my family build a successful entrepreneurial venture in the textile industry and attending the Escuela Suiza, a local Swiss school and one of the oldest international schools in Barcelona, as a kid.

Speaking several languages and traveling was a gift that opened my eyes to the global world. After studying Economics in Barcelona and in The Netherlands, I pursued an MBA at IESE Business School. The entrepreneurship class awakened my entrepreneurial spirit and led me to co-found Advance Medical.

Starting and growing Advance Medical, which eventually became a pioneering and multinational telehealth company, was a fascinating life experience. For 20 years, my co-founder and I established operations in more than ten countries with a global workforce of over one thousand workers to help tens of thousands of patients every day around the world.

When Advance Medical was acquired by US-based TELADOC, I was ready to move forward to new challenges. One meeting with Marta during one of her first trips from California to Spain was enough to understand that Nina Capital was exactly the next thing I wanted to do: build a Venture Capital firm based in my city, Barcelona, and ready to support European need-driven founders building health tech companies with international ambitions.

That this remarkable concurrence of events--her first landing in Barcelona, my exiting Advance Medical after an adventure two decades long--occurred without apparent causal connection is yet more proof that so much of life is about timing, and is one the ingredients that makes Nina Capital’s origin story special.

I am a genetic cocktail of Norwegian and Cypriot DNA raised in an international environment, which precipitated into what some call a “third culture” identity; a blend of contradiction with Mediterranean and Nordic culture. Barcelona is my latest home and I could not have picked a better place to feed my insatiable appetite for the ocean, paddle boarding in the summers and surfing in the winters (yes, you can surf here on a weekly basis), and generally anything outdoors with some adrenaline sprinkled on top;  a couple of hours drive to the Pyrenees for hiking in the summers and skiing in the winters.

I also love music, with a near-criminal collection of obscure instruments from all over the world. I do play on occasion; piano, guitar and trumpet are my forte, with a particular interest in playing jazz and funk. You are just as likely to find me at the Palau de la Música enjoying the works of Chopin, to a Black Keys concert, to a dingy jazz “hole-in-the-wall”, to a Joris Voorn event.

A fascination with what makes us tick led me to study neuroscience at the University of Edinburgh with a focus on the biological basis of cognition and memory. I loved Edinburgh so much I stayed to pursue a masters in innovation and management focused on the bioeconomy as a segway into the healthcare innovation space. I ended up, after a stumble or two, at UCL in London where I stayed for four years working out of their commercialization and technology transfer company, UCLB. My time there introduced me to the world of early stage healthcare commercialization; bridging the realm of lab research to the real world through intellectual property strategy, to negotiating licensing deals, to startup company creation.

A yearning for a smaller city and sunshine led me to Barcelona to pursue an MBA at IESE business school; a two-year life-changing rollercoaster that only those with a similar experience can comprehend. I joined Nina Capital as an MBA summer intern and was fortunate enough to be given the opportunity to stay. I could not have found a better place to call home.

I was born in Israel, and here I grew up in a small place tucked away in the mostly empty land between Jerusalem and Tel Aviv. Life in Tel Aviv was better suited for my personality, and I called this cosmopolitan city home for eight years before the warmth of the weather and of the people of Barcelona caught my imagination.

I have a creative soul with an analytical mind—the very obvious result of growing up in a family made of artists on one branch of the tree, and accountants on the other. My appetite for testing new things led me very early to try any kind of medium in plastic art from oil painting to carving in marble. Growing up with a passion for art, I was certain to eventually become an Architect. This was not a passing phase: I carried this ambition for eight years. All it took was one lecture in the school of Architecture to change my mind, leading me to the resolution that what I really wanted to do is conquer the world. Just kidding.

Jokes aside, I really was increasingly intrigued by the powers that move the world. To study Law and Economics felt a natural choice to satisfy this curiosity. Before proceeding to world domination, however, I had to travel and learn more about it. With a 15kg bag on my back I hiked through the mountains of Chile and chilled at the beaches of Costa Rica, resulting in a new desire to engage in an international environment.

Having returned to Israel and fast forwarding to years later, I began working for a large investment house in Israel, investing in Alternative Assets. Specifically, I was sourcing, analyzing, and negotiating opportunities for investment in private companies, VC/PE funds, and Hedge funds. I love being challenged and creating challenges—and the investment world was filled to the brim with hard problems to solve, new strategies, and ideas predicated on weak assumptions.

However, the desire for an international experience had never truly left me. It eventually led me to pursue a two-year MBA program at IESE business school in Barcelona. My inner architect was also restless, constantly wanting to build. This is what led me to Nina Capital. One email led to an MBA summer internship and eventually to a very fortunate opportunity to stay and work.

When I am not working, I am probably working out in the gym, roaming the streets of Barcelona with my marvelous (and slightly spoiled) rescue dog, or simply enjoying a glass of wine in one of the many breathtaking terraces that Barcelona has to offer.

Born and raised in Barcelona, I am the youngest member of Nina Capital but also one of the first to join the firm a few months into its existence.

Like most of us here, my path to venture capital was non linear. My obsession for dinosaurs as a kid almost led me to study paleontology, until I came upon biotechnology—and if there is something better than studying dinosaurs, it is being able to create them! Unfortunately, only later did I learn that we were still a bit far from this scientific milestone. It turned out to be, however, just the right choice for me.

During my studies in biotechnology at one of the leading schools here in Barcelona, Institut Químic de Sarrià, I discovered the world-changing potential that life sciences will have in our lives in the years to come. In less than a decade, my feelings of disappointment about our limited ability to modify only the genome of living systems before they were born left way to the excitement of seeing that, today, we already have gene therapies that rewrite the code of life as it's unfolding. We are rewriting the pages of a book as it’s being read. What the future of life sciences holds for us, we can only find in science fiction books.

With so many possibilities, it did not feel right to go into research and commit to a single one. In the meantime and during my last years of university studies, I had developed a strong interest in finance. This newly discovered passion led me to start working in management consulting for the banking industry, where I learnt a great deal of finance—but missed the spirit of science.

A new mission started forming, to dedicate myself to help with access to working capital all the amazing technologies that will be born in the next decade go from idea to reality. Shortly after, I met Marta and resonated deeply with the idea of Nina Capital. The rest, as they say, is another funding round.

Partner at Asabys, Sylvain joined the firm in 2018 from Ysios Capital. At Asabys, Sylvain is involved in the sourcing, execution, and management of our investments in the biopharma and medtech segments. He currently serves on the board of directors of Anaconda and is an observer on the boards of Inbrain Neuroelectronics, SpliceBio and Medlumics.

Previously, Sylvain spent a decade in academic labs both in France and the US, working specifically in the fields of gene therapy and regenerative medicine. He was a postdoctoral fellow in the department of Genetics and Genomic Sciences at the Mount Sinai School of Medicine in New York following the completion of his doctoral thesis at INSERM.

Sylvain obtained his Ph.D. in Molecular Medicine from University of Nantes, holds a master’s degree in biotechnology with honors from University Paris XII, and an MBA from Esade Business School in Barcelona.

Maite joined Asabys in 2019 and she is primary focused in the analysis of relevant investment targets within the health-tech industry, carrying on due diligence processes and providing support to portfolio companies.

Prior to joining Asabys, Maite led the Business Development and Digital departments at Sphera Global Healthcare, telemedicine company with operations worldwide. Previously, she was a Business Development Analyst at Antai Venture Builder, conducting market analysis and incubating digital companies. Maite started her professional career at Deloitte Corporate Finance, unit responsible for M&A and debt restructuring operations in Spain.

Maite holds a bachelor’s degree in International Business from Universitat Pompeu Fabra (UPF) and the University of Florida (Warrington College of Business), and a master’s degree in Digital Marketing by ISDI.

Entrepreneurial-minded executive with over 10 years of increased responsibilities in key management positions in Business Development and Strategy in Europe, USA, Middle East and Africa. As a hard-worker and proven business leader, with both an analytical and strategic mindset and with multi-functional business capabilities, has consistently met or exceeded sales and profits targets by adopting innovative strategies.

Venture capital investor at Mercia Asset Management, focused on making investments of £1m - £3m (with the ability to follow on up to £20m) into life science and technology focused companies in the UK.

Previously, I held corporate strategy and M&A roles at Verastar, a Vitruvian Partners’ portfolio company, and Grant Thornton UK LLP. I also hold a PhD in Pharmacology from the University of Liverpool’s MRC Centre for Drug Safety Science.

Arnaud joined Illumina Ventures in 2022 as a Principal and Head of European Operations. Based in Amsterdam, Arnaud brings 15 years of experience in life science R&D and venture investment in the biopharmaceutical industry.  

Before joining Illumina Ventures, Arnaud was an investment director for the biotechnology team of M Ventures, the corporate investment arm of Merck KGaA, based in Amsterdam. There he was instrumental in the investment in Scipio Bioscience, Pictor Labs and Nanosyrinx, among other companies. Arnaud started his investment career in Paris at Seventure Partners, where he invested in life sciences companies including Microbiome and Digital Health. Before joining Seventure, Arnaud was a senior financial auditor at KPMG in the healthcare business unit based in Paris.  

Arnaud earned his Ph.D. in Immunology from the Pasteur Institute in Paris and continued his scientific career with post-doctoral work in Oncology at the Trinity College, Dublin. He gained his MSc in Finance from ESCP Europe, Paris.

Bio coming soon.

Managing partner and co-founder of Asabys. Clara currently serves on the board of directors of Ona Therapeutics, Origo Biopharma, Sidekick Health and Nuage Therapeutics.

Formerly, Clara served as Strategy & Development Director at Kern Pharma and held several positions at Advancell, including being the managing director. Clara has served as a member of the Investment Committee of the venture capital firm HealthEquity (2015-2018), as well as vice-president of CataloniaBIO (2014-2017) and member of the Board of Directors of Biocat (2015-2017).

Clara received her Doctorate in Pharmacy in 2004 and a Master’s in Pharmacy from the University of Barcelona in 1999.

Antonio joined Asabys in 2022 as a Senior Associate. He is responsible for evaluating novel opportunities across multiple therapeutic areas in Biotech and HealthTech. 

Antonio joined Asabys after working as Investment Analyst at Inkef Capital where he supported the Healthcare team with deal sourcing and the analysis of investment opportunities. Prior to Inkef, Antonio was an Innovation fellow at the Novo Nordisk Foundation Biomedical Design Programme in Copenhagen, where he co-founded a digital health start-up. 

Antonio has 9 years of scientific research experience, working at the interface of drug discovery, biology and biophysics. He earned a Ph.D. in Drug Discovery from the University of Naples Federico II, and was a postdoc at FMP-Berlin and at Stanford University.

Isabel started at Asabys in 2022 as an Associate. She is responsible for evaluating novel opportunities from a scientific and strategic perspective focused on the biotech sector.

Isabel joined Asabys after working at Ysios Capital where she screened and analyzed deal flow while conducting due diligence on companies developing novel therapeutic approaches. Previously, Isabel spent 7y+ as a researcher in immunology and oncology. She completed her doctoral thesis at Vall d’Hebron Institute of Oncology (VHIO) in hemato-oncology.

Isabel earned a Ph.D. in Medicine from the University Autònoma de Barcelona (UAB), a MSc in Advanced Immunology from the University of Barcelona (UB), and a BSc in Biochemistry. She also holds an Executive MBA from ESADE Business School.

Associate at Asabys, Anna is responsible for sourcing and assessing opportunities from the scientific, development and business perspectives.

Previously, Anna was Investment Analyst at LSP where she was responsible for the initial deal flow screening and in-depth scientific and clinical due diligence on investment opportunities. Anna also served as Innovation Manager at the Knowledge and Technology Transfer Office at Hospital Clínic de Barcelona and its Research Institute IDIBAPS where she advised entrepreneurs on intellectual property protection and commercialization strategies. Before, Anna was a researcher in the Growth Control and Cancer Metastasis group at the IRB Barcelona.

Anna was awarded a PhD in Biomedicine from the University of Barcelona (UB), a master’s degree in Biomedical Research from the Pompeu Fabra University (UPF) and two bachelor’s degrees, in Chemistry and Biochemistry, by the University of Barcelona (UB). Anna combined her studies with scientific research training in several research groups in Paris and Barcelona.

Dr. Anke Cassing has many years of experience in strategic marketing and business development in medical technology, biotechnology and in pharmaceutics. She holds a doctorate in biology and studied economics. Before joining the HTGF, she developed the product portfolios of international companies ensuring their future growth.

Born in Germany, raised biculturally in Portugal, Jakob is fluent in four languages (German, English, Portuguese, Spanish). Outside of work, he is a passionate surfer and sports enthusiast. He holds a Bachelor’s degree in Economics with a semester abroad in the US and recently completed a double Master’s degree in Management, specializing in Innovation and Strategy. His first real contact with venture capital was during his Master’s thesis on ‘Corporate Venture Capital (CVC) investment relationships from the perspective of Tech-oriented Start-ups’, where he analyzed the motivations, concerns and protection mechanisms for start-ups when accepting CVC investments. In addition, he worked as a teaching assistant in strategy and entrepreneurship courses for Maastricht University and prepared an industry-specific target market analysis on ‘E-Health in Portugal’ for German companies wishing to enter the Portuguese market on behalf of the BMWi.

Montserrat Vendrell is founding partner of Aliath Bioventures SL and a partner at Alta Life Sciences SL. She is Board Director at Peptomyc, Accure Therapeutics (Chair), Ona Therapeutics and Board observer at Inbrain Neuroelectronics and is involved in multiple startup mentorship programs. Dr. Vendrell has over 10-years of experience in biomedical research both at Spanish institutions (CSIC) and international companies (Roche Institute of Molecular Biology), and +20 years in supporting entrepreneurs in life sciences. Montserrat was part of the founding team of Barcelona Science Park, its bioincubator and technological platforms (Deputy CEO and later, CEO). Dr.Vendrell was also founder and CEO of Biocat, Catalonia biocluster, one of the most successful in Europe. She was CEO of Biocat for 8 years. Additionally, Dr. Vendrell chaired since its birth until 2015 the Council of European Bioregions. Dr. Vendrell holds a PhD in Biology from University of Barcelona, a master’s degree in Science Communication from Pompeu Fabra University and an Executive Degree in General Management from IESE Business School, Dr. Vendrell currently chairs the Executive Committee of the Pasqual Maragall Foundation (Alzheimer’s research) and the Board of Trustees of UPF (Pompeu Fabra University).

Liliane joined Oxford Science Enterprises in December 2019, bringing over a decade of experience across genetics research and digital innovation in health systems.

At OSE, Liliane focuses on uncovering early-stage ideas and building new businesses at the intersection of healthcare and technology.

Previously, Liliane worked for the World Health Organization, evaluating technologies to improve access to care in indigenous and refugee communities, and co-ordinating global guidance for the use of digital health in diabetes, hypertension and smoking cessation.

As a Global Health Policy Fellow at Imperial College London, she advised on the reform of undergraduate medical education in Myanmar. As Deputy Head of the NHS/Foreign Office joint unit for the UK Prosperity Fund, Liliane led on a global strategy to facilitate exchange of technology and healthcare best practices with countries in Latin America, Africa and Southeast Asia.

Liliane completed her PhD in Human Genetics at the University of Oxford as a Canadian Rhodes Scholar.

Heather joined Oxford Science Enterprises in March 2022, a highly experienced venture capitalist, with over 20 years investment and company building experience.

At OSE, she leads the Health Tech team to identify new opportunities, catalyse the creation of transformational new businesses, and scale up the existing portfolio, covering digital health, diagnostics and medical devices.

Heather started her career in operational roles, creating new healthcare-related businesses and spin-outs for Unilever. She transitioned to investing while at Unilever, and subsequently spent the next 15 years in venture capital, more recently with J&J, leading J&J’s consumer Health Tech investment and partnering across EMEA.

She joined OSE from Optum Ventures where she was a Partner, responsible for establishing and leading the Global Health Tech investment fund on behalf of Optum, a leading technology-enabled US health services business, part of UnitedHealth Group.

Heather holds a PhD in Clinical Biochemistry from Queen’s University of Belfast.

The new European Innovation Council (EIC) is the first VC-inspired performance-driven tech investment vehicle set up by the European Commission.

We invest at seed, early-stage or Round A. My role is similar to that of a partner at a private VC, in that I identify technological areas with high potential, direct focus of our investment efforts towards these areas, participate in the selection of target companies and manage the portfolio post-investment.

Internationally experienced senior executive, medical doctor, venture partner and Board member passionate about improving access to high-quality healthcare and delivering better health outcomes. Extensive experience across the health sector including medical insurance, health services, population health and digital healthcare. Worked across the world in UK, US, Middle East and Asia taking on clinical, strategic, operational, and consulting roles. Over 20 years experience as a doctor specialising in family medicine including mental health. Led large multi-functional global teams, advised business and government, and founded global ecommerce businesses. Board adviser to start-ups and Non-Executive Director at BMJ Publishing Group.

Philipp Lechner joined TVM in 2020.

Prior to joining TVM, Philipp worked for the Global Healthcare Team at Société Générale Corporate & Investment Banking. In this role he worked on several cross border M&A transactions in different healthcare industries.

He holds a Master degree in International Finance and Economics from the Nuremberg Institute of Technology with a focus on Financial Markets and Corporate Finance and did additional business and finance studies in London, UK and Nuertingen, Germany. During his master thesis he has already worked closely with TVM analyzing financial decision making in life science VC investing.

Kelly Krajnik is a senior director for business development with Mayo Clinic Ventures (MCV). Prior to joining MCV in 2006, Krajnik worked at Mayo Clinic as a senior research technologist in the microarray core facility, was a member of the Institutional Review Board, and worked in the Department of Laboratory Medicine and Pathology to develop new molecular diagnostic assays. Krajnik is a senior member of MCV’s management team. Among her responsibilities, Krajnik leads business development efforts for the Center for Individualized Medicine’s Microbiome Program, including Mayo Clinic’s engagements with companies in the microbiome space.

Alex was previously Co-Head of Life Sciences Research at Kempen & Co, with extensive experience in European biotech and medtech.

Alex will lead Bryan Garnier’s team of seven healthcare analysts based across Europe and the UK. In addition to traditional equity research, the team’s focus will be on developing differentiated thought leadership that identifies long term trends shaping the future of the healthcare sector.

Bio coming soon.

Top-performing marketing leader with expertise in creating, launching and fostering successful initiatives. Clear communicator with a proven track record of executing marketing strategies to achieve business objectives. Demonstrated ability to work effectively cross-functionally and internationally with internal and external partners. Known for building strong relationships and effective project management.

Create strategic growth options for Johnson & Johnson MedTech by investing in emerging health care businesses

Seasoned healthcare executive with successful track record at establishing strategy, securing resources and executing both in the corporate and venture backed world. Expert in analytics applied to commercial and clinical operations in biopharma and health systems. Unique breadth of experience across the healthcare eco-system: payor, provider, supply chain, biopharma and health IT companies. Deep understanding of stakeholder dynamics and value creation opportunities

A strong technical and commercialization leader with broad general and start-up management experience in life sciences and medical device industries. Proven track record of identifying and addressing significant unmet clinical needs with innovative technology solutions. Over 25 years of experience in the development and commercialization of therapeutic medical devices, including start up formation, fundraising, team building, R&D management, clinical and pre-clinical strategies, operations, and general management. Over 35+ issued and pending U.S. patent applications.

Founder of Conceptus, ProDuct, CardioMind, Pivot Medical

Specialties: New company formation, new technology commercialization, fund raising, IP strategy, commercialization and development strategies, pre-clinical and clinical investigation strategies, thought partner and mentor of individuals and teams.

Joe Mullings has been building companies and careers since 1989. He is the Founder, Chairman and CEO of The Mullings Group, including TMG Search and Dragonfly Stories. The search firm, with over three decades in the industry, is responsible for more than 8,000 successful searches in medtech / healthtech / life sciences with clients ranging from multi-billion-dollar companies to emerging high-tech organizations worldwide. TMG’s international presence and work with over 800 companies allow them to provide solutions with the clients they partner with across the globe.

As the first search firm to integrate media and talent access, Dragonfly Stories was launched as a media production company, complete with a state-of-the-art studio, for use by clients and partners for attention and awareness. Dragonfly is the media machine behind the 7-time Telly Award Winning video docuseries, “TrueFuture,” of which Joe is the host. He is also the founder of TMGPulse, a MedTech news and opinion website. He holds an engineering degree from The University of Dayton, Ohio.

Strategic thinker and versatile corporate development professional from a unique cultural background (Born in USA, raised in Bolivia & Germany, currently living in Spain), who seeks challenging opportunities in corporate portfolio revitalization via expansion into adjacent and whitespace healthcare markets. Extensive experience, strong skills-set, and acumen in securing leadership team consensus around strategy recommendations and executing deals to transform existing business boundaries and thereby increase enterprise value.

As a seasoned healthcare executive with over 18 years of experience in the MedTech industry, I have a proven track record of leading and managing commercial teams across diverse markets and segments. My core competencies include sales, strategy, marketing, product development, key account management, and new business development, with a focus on delivering sustainable, profitable growth and innovation.

 At Medtronic, I was responsible for driving sustainable, profitable, growth and innovation; managing a team of cross functional experts with a revenue of over $880M. I successfully launched several new products, secured multiple large contracts, and established strategic partnerships with key stakeholders and customers. I also championed a culture of collaboration, diversity, and excellence, aligned with Medtronic's mission and values.

Bio coming soon.

I´m a passionate scientist. I have a PhD in Pharmacology, an MSc in Management and Development of Biomedical Technologies, and a Graduate in Biology. In the last years, I have focused on neurological disease, concretely in stroke. I have worked in translational research projects, focusing on preclinical drug R&D and clinical research. Previously, I have been woring on clinical research projects on the benefits of mediterranean diet products in patients with metabolic syndrome.

I am a person with initiative, strong management and communication skills. I have critical thinking, problem-solving skills, and the ability to work well in a team environment. Throughout my professional career, I have developed and acquired skills that allow me to adapt easily to new challenges.

Anne has been running Sofinnova's in-house MedTech accelerator, MD Start, since she came on board as a partner in 2015.

She embodies the MD Start team’s hands-on approach: Anne is the founding and current CEO of both Gradient Denervation Technologies and Moon Surgical. She is a Board member of both SafeHeal and May Health — two companies where she was also founding CEO.

“What I like about this job is that it is about building products and companies,” Osdoit says. “It is very diverse. It is in different therapeutic areas, in different spaces with different technologies.”

Prior to joining Sofinnova, Anne held several key positions at Mauna Kea Technologies, a Paris-based medical technology company with global presence, developing a disruptive “optical biopsy” technology. She was closely involved in multiple financing rounds, including the company’s initial public offering on the Paris Euronext, a highly successful operation and the largest public listing for the sector that year.

Anne is an active angel investor and an independent board member of FeetMe and Cardiologs Technologies, two Paris-based e-health startups. Cardiologs was purchased by Philips in 2021.

Anne is a trained biomedical engineer from Ecole Polytechnique of Paris, France and Johns Hopkins University in Baltimore, Maryland. She holds additional degrees in Biostatistics and epidemiology applied to clinical trials (Université Pierre et Marie Curie), as well as Corporate Finance (London School of Economics).

Vijay offers a unique perspective as our only medical doctor turned investment banker and VC.

Before Optum Ventures, Vijay was a life science partner with Catapult’s GM&C Life Sciences Fund leading and managing investments across life sciences with a specialist focus on digital health. Vijay has invested in data driven companies targeting respiratory health, complications of diabetes, patient safety, consent and education.

Prior to this, he was chief investment officer at a health care IP commercialisation company focused on digital health, diagnostics and therapeutics investments. He was previously a health care investment banker at Peel Hunt and Piper Jaffray, looking after listed health care clients as well as undertaking IPO, M&A, private placement and secondary fundraising transactions.

Vijay began his career in medicine and worked as a doctor for the NHS.  He qualified from Guy’s Kings and St. Thomas Medical School in London and holds a MBBS in Medicine and a B.S. in Development Neurobiology.

Cécile joined the Sofinnova MD Start team in 2019. She is currently CEO of BrightHeart, a Sofinnova MD Start III portfolio company. She also brings her operational and strategic expertise to Endoron, another investment from MD Start III, to accelerate the development of the company's highly disruptive technology. 

Prior to that, she was CEO of HEPTA Medical, COO of Gradient Denervation Technologies, and director of clinical, regulatory and market access at SafeHeal, the first company created by MD Start II, where she managed the execution of the first-in-human study and regulatory approvals in the EU and US.

Unofficially, she is MD Start’s regulatory expert.

“We need to make sure we start with the right strategy from the get-go because the regulatory strategy is one of the key drivers of the entire project,” she says. “It will drive the clinical strategy, but also the R&D strategy. This is really a key entry point for the project.”

Prior to joining MD Start, Cécile held various clinical, marketing and regulatory positions in both mature and start-up medical device organizations in the fields of endoscopy, pulmonology, dermatology, surgery and diabetes care; for single and multi-use disposable products and capital equipment.

Cécile holds a bachelor’s degree in biomedical engineering from UTC (Université de Technologies de Compiègne) in France, Dalarna University (Sweden) and Favoloro University (Buenos Aires) in Argentina. She also has a degree in corporate finance from HEC in Paris.

My professional goal is to use my expertise and passion for medical science in the identification and development of new technologies that improve patient care.

Evan joined Thuja Capital as an investment director and partner in early 2023.  Prior to that, he was Partner and Head of European Investments for Philips Ventures, the corporate venture capital group of Philips.  During his tenure, Evan led and managed numerous investments across healthcare sectors, including medical device and digital health, and across investment stages from early to growth.  Before joining Philips Ventures, Evan was the Chief Business Officer of the U.S.-based venture backed precision biology company, RareCyte, which he helped lead from product concept to international commercialization.  Evan holds an M.B.A with Distinction from the University of Oxford.

Specialties: Business Development, M&A, Strategic Planning and Corporate Strategy, Strategic Marketing, Medical Technology and Startup Assessment and Evaluation, Due Diligence, Integration, Licensing and Partnering

Chris joined Medtronic as the Senior Manager of Business Development in August of 2011.  He oversaw Medtronic’s global inorganic growth strategies and opportunities for Coronary business, and was promoted in June of 2012 to expand his Business Development responsibilities to include the Renal Denervation business.  In April of 2013, Chris was promoted to Director, overseeing Business Development functions and leading a team of professionals. In September of 2014, Chris was promoted to Senior Director, Business Development for the Coronary and Structural Heart business unit for Medtronic, and in February of 2016, Chris was promoted to Vice President of Corporate Development.

Chris has more than 18 years of successful professional experience, of increasing responsibilities, with the majority of his experience in a business/corporate development and strategy capacity within the pharmaceutical and medical device industries, in addition to Medtronic, including Allergan, Watson, Agilent Technologies and Peregrine Pharmaceuticals, where he was Vice President of Business Operations.

Chris holds an MBA from Concordia University and BA in Public Relations, Communications from California State University, Fullerton.

Mano Iyer, a serial entrepreneur whose ties with Sofinnova Partners stretch back more than 15 years, rejoined the firm in October, 2022. As a Venture Partner, Mano investigates global medical device investment opportunities across the Sofinnova Partners platform of strategies, with a particular focus on helping the firm’s in-house medtech accelerator, Sofinnova MD Start, incubate world-class companies.

Bio coming soon.

Raúl oversees and coordinates the identification and evaluation of investment opportunities from both scientific and business perspectives at Ysios Capital.

Prior to joining Ysios in 2008, Raúl first worked in corporate business development (Licensing In and Licensing Out) at Laboratorios Almirall. He was subsequently responsible for developing and managing the business of the Company in the Americas and Africa through licensees and distributors.

Raúl was initially trained as a researcher in central nervous system pharmacology within the Department of Pharmacology of the University of the Basque Country (UPV-EHU), and in neurochemistry within the Department of Neurochemistry at the Institute for Biomedical Research of the Barcelona–Spanish National Research Council (IIBB-CSIC).

Raúl holds a Bachelor’s degree in Biological Sciences from UPV-EHU, and a PhD in Neuroscience from UPV-EHU and the CSIC.

Kai’s is a seasoned medical device leader and digital health entrepreneur. Over the last 18 years, Kai has driven the global expansion of the healthcare focused design and innovation firm Worrell Inc (now part of Veranex), and has created significant returns for investors after successfully exiting a venture backed digital health firm Geneva Healthcare.  

Kai currently serves as Veranex's Executive Vice President of Corporate Development leading the M&A activities for the firm and sits on the Corporate Leadership Team.

Venture Builder in the healthtech industry, bringing early stage innovation to the patient by founding startups. Background in genetic engineering, cell and molecular biology. Experience in strategy consulting and venture capital. Passionate about innovation, sustainable impact, tech solutions.

Bio coming soon.

Julie is an Analyst at iGan Partners. As a member of the investment team, she is responsible for deal origination, due diligence, and research activities. Before joining iGan Partners, she worked in marketing within Janssen’s (J&J) portfolio of oncology brands, and in corporate strategy at a Toronto hospital.

Julie holds a Bachelor’s degree in Biochemistry from Queen’s University, and an MBA from McMaster University.

Maryline is a MedTech and Life Sciences expert with 20+ years of business and digital transformation experience. She focuses on improving patient outcomes by designing healthcare solutions that prioritize patients and digital tech. Maryline previously held sales and marketing management positions at Becton Dickinson and Janssen, led commercial operations at Singapore-based health tech start-ups, and was responsible for 31 countries' patient engagement strategies and new partnerships at Novartis. She holds a double master's degree in European business and management from EDHEC Business school, an MBA from INSEAD and executive certification in AI from MIT.

Specialize in the areas of international commercial law, with a focus on private equity, foreign direct investment and cross-border M&A, antitrust, and capital market. Admitted to the Chinese bar in 1992. LL.B. from Peking University in 1990, and an LL.M and PhD from Xiamen University in 1993 and 1996, respectively. Was a partner in two other prominent Chinese law firms, a manager of the international headquarters of a Big 4 firm’s legal practice in Paris, and a lecturer of law at Xiamen University.Joined EY Chen & Co.in 2006. In 2012, appointed by the All China Lawyers Association as the vice director of the Antimonopoly Law Committee. In 2010, the Shanghai Bar Association appointed me to serve as the vice-director of its International Investment & Antimonopoly Research Committee, and in 2011 it promoted me to serve as director of this committee for a three year term. The author of numerous works on international economic law and dispute resolution. In 2009, invited to serve as a guest research fellow at Xiamen University’s International Economic Law Institute, and in 2010, appointed to serve as guest professor.

I am a Corporate Finance Director at Goodbody. I have over 20 years of healthcare business development and corporate finance experience focussed mainly on the medical device and pharma sectors, advising on capital funding, M&A and strategic development.

Bio coming soon.

As an investor and business-outcomes focused professional with over 12 years of experience in consumer insight and growth strategy consulting, I have a strong track record as a trusted advisor to large brands and investing in and mentoring start-ups in the healthtech space.

My passion lies in scaling-up and supporting companies seeking to transform the lives of patients, consumers, and HCPs, driving impact, problem solving, and building effective strategies.

Finance and Technology executive with over 20 years of experience with a leadership style that inspires teamwork and excellence to manage complex and new situations.

Proven track record of driving organisations to growth using extensive technological and digital industry experience in addition to a clear business vision which has resulted in demonstrable increased company value year on year.

Experience working collaboratively with sophisticated investors building relationships and synergies with senior stakeholders. Broad range of management experience, knowledge of finance, risk and global operational strategies, M&A, multilingual (fluent English and Spanish) and highly motivated by new challenges.

Bio coming soon.

Senior-level Executive with extensive international experience in leadership and board positions at public and private companies within the Health Care and Medical Technology Industry.

Highly analytical decision-maker with proven track record in building, turning around and operating companies, along with proven history of increasing productivity, delivering profitable growth and developing talents

In-depth understanding of Health Care market access dynamics, emerging medical technologies assessment and related commercial applications.

Motivated self-starter with an authentic and engaging leadership style focused on patients, customers and employees.

Experienced Global Executive with a demonstrated history of working in the medical device industry. Skilled in Executive Management, Medical Devices, M&A, Sales Management, and Global Management. Strong information technology professional with a Master's Degree focused in Healthcare Administration- School of Public Health from University of California, Los Angeles. Fellow American College Healthcare Executives.

Technical leader in Medical Device development; turning new ideas into life-changing products.

I am a Chartered Engineer and member of the IET with over twenty years' experience in developing electronics and embedded systems ranging from low-cost consumer devices to highly-specialized sensor and instrumentation products. I have worked in a wide variety of industries including medical technology, inkjet printing, laboratory instrumentation and automation, utility metering, and cryptography.

Since 2014 I have been developing Medical Devices ranging from connected inhalers and smart implants to complex diagnostic instruments and surgical robots. My particular areas of expertise are in technical leadership of multi-disciplined project teams, systems thinking, formal verification testing, and product development for regulatory compliance, especially IEC 60601.

Growing the Global Medical Technology Group of Cambridge Consultants, one of the world's leading technology companies, providing Research, Design & Development Services, and Management Consultancy to the Healthcare Industry. I lead the Business Development for a team of experts focused on Surgical, Interventional, Medical Wireless and Hospital Product Development. Strong client relationships are key to our success. Disruptive Technology, Human Factors and the Front End of Innovation is where we excel and provide value.Client goals are managed and accomplished, often within aggressive cost and time constraints.

Bio coming soon.

Extensive background in business transformation & development, principal investing and organizational leadership.

Bio coming soon.

Steven M. Gottlieb, M.D., is a physician executive and healthcare serial entrepreneur who seeks innovative companies in which he can invest, add value and accelerate growth. Dr. Gottlieb has more than 30 years of senior leadership experience in the healthcare industry, and has founded, managed, funded, grown and exited several successful healthcare companies.

Dr. Gottlieb served as CEO of TeamHealth Anesthesia, the national anesthesia division of TeamHealth (NYSE: TMH)—one of the largest providers of outsourced physician staffing solutions for hospitals in the US. 

He was co-founder, CEO and president of Anesthetix Management—a leading national provider of anesthesiology and pain management service solutions to hospitals and surgery centers. Dr. Gottlieb successfully led the company through its growth and development, including a private equity investment by Summit Partners in 2006, its acquisition by TeamHealth (a Blackstone company) in 2009, and an IPO in 2010. 

Dr. Gottlieb has led or participated in a range of successful investments in a variety of early-stage growth companies, both inside and outside of the healthcare industry. Among other things, Dr. Gottlieb currently serves as Chairman of J10x, an organization which functions as a strategic operating partner to early-stage entrepreneurial companies and helps accelerate their launch, growth and success in the US market. 

Pierre joined Amadeus in 2012 and is a Partner in the Early Stage Fund. His current focus is on the Health and Bio sectors.

He led our investments in and is on the boards of portfolio companies such as advanced wound therapy specialist Natrox, cell and gene therapy manufacturing platform OriBiotech, protein degradation leader PhoreMost, imaging biomarker pioneer Quibim, patient review leader Doctify, computer vision platform V7, and Parkinson’s therapy developer Charco. He also oversees whole-genome interpretation platform Congenica, care pathway optimization leader Lumeon, cell manipulation platform Sphere Fluidics and organ transplantation leader Organox.

Prior to joining Amadeus, Pierre was first an analyst at Natexis in France, before becoming an entrepreneur with PE backed biotech Avesthagen in India where he joined the founding team and helped grow the business over a decade. During his tenure, he became CEO of its Bionutrition division (350 employees) before taking over as Chief Strategy Officer for the group, with research activities spanning from medical nutrition and agri-tech to population genetics.

Pierre holds a MSc in Maths and Econometrics from Aix-Marseille University, France and graduated from executive programs at Stanford, MIT and Harvard. Pierre is fluent in French and English.

Bio coming soon.

Bio coming soon.

Howard Kim joined Asahi Kasei America in 2016 and is based outside Boston, MA. He is a Managing Director, focusing on healthcare investments. Prior to joining Asahi Kasei, Howard worked at Advent International, a global private equity firm, and Hambrecht and Quist Capital Management, a healthcare investment firm. His operational experience includes working as Chief Medical Officer and Vice President of Business Development at a venture-backed medical device company. Howard received his BA from Harvard College and his MD from Tufts School of Medicine.

Bio coming soon.

I would like to pursue my career in venture capital in the healthcare sector. Indeed, I wish to use my dual skills in identifying and supporting high-potential startups that can represent both investment opportunities and significant improvements in healthcare. Bilingual, analytical, sociable and a good listener, I am eager to take on new challenges.

Sophie spent 20+ years in General Management roles in Blue chip companies and in Start-ups. As CEO, Sophie was CEO of CIT, the largest preclinical company in France, that she rebranded as Citoxlab, after acquiring additional businesses, and served as CEO of Cellnovo, developing and commercialising and e-connected insulin micro-pump. As CEO, Sophie raised around €80m and listed a company on Euronext in 2015. Amongst other key roles, Sophie served as GM for the in-vitro Diagnostics business of J&J France, as VP North EU for Sorin Group (now Livanova) across 5 BU in the cardiac sectors and Dialysis and as VP Sales and Marketing EU, Lifecell, in reconstructive Breast, Abdominal, Pelvic floor surgery. Along the years, Sophie has driven product development, industrialisation, market access and commercialisation in all geographies. Sophie's education is Engineering in Biotechnology, PhD in Immunology and MBA.

Mr. Marcantonio is a Principal of Madryn Asset Management, LP where he works with the firm’s investment team to source, evaluate, and manage investments in the healthcare industry. Prior to Madryn, Mr. Marcantonio was an Analyst at Lombard Odier Asset Management, as a member of the 1798 Global Partners fund, a long short equity fund, where he was responsible for investments in the biopharmaceutical industry, from 2015 through 2017.

Prior to Lombard Odier Asset Management, Mr. Marcantonio worked at Orchard View Capital, a long short equity fund, where he was responsible for investments in the healthcare industry. Prior to Orchard View Capital, Mr. Marcantonio worked at Citigroup in the healthcare investment banking group, where he worked on various public and private financings and mergers and acquisitions transactions.

Mr. Marcantonio graduated with honors from Lehigh University with a BS degree in Finance & Accounting.

An inventor of BioBrace, a novel reinforced bioinductive scaffold for soft tissue healing. Medical device engineer with well-rounded experience suited for a variety of projects/tasks. Proficient in designing, executing and documenting experiments, project management, operations, drafting and reviewing manufacturing documentation, quality assurance and implementing controls, performing literature research and reviews, performing prior art searches and reviewing intellectual property, and assisting in fundraising through research and by understanding the key players in the industry. If you need something to get done, I'm your guy!

Bio coming soon.

Cenponts is a global cross-border boutique investment bank specialized in healthcare investment & partnering, based in Paris, Berlin, Basel, Shenzhen. Our key competences are our expertise in cross border healthcare transactions and top level network with leading healthcare funds and companies in China/Europe/US. Cenponts has closed >7B$ global cross border healthcare transactions. For example: Genfit/Terns 228M$, Avilex Pharma/Simcere 175M$, Pharnext/Tasly 50M$, Domain series A 40M$, Skymedic/Wondfo 20M$ etc.

Bio coming soon.

Allan Fisher's entrepreneurship spans over 50 years covering a wide range of sectors from hospitality, fitness, bio-tech, fin-tech, and property. Allan has served as CEO and Chairman of publicly traded health and fitness companies, and, as founder of Holmes Place 40 years ago, is regarded as one of the industry veterans that established the sector in the UK. Currently Allan holds the role of Chairman in Holmes Place Brands, as well as a variety of non-executive director positions.

Bio coming soon.

Bio coming soon.

I’m passionate about helping companies grow, especially by supporting them from a financial perspective. I very much appreciate working, discussing and exchanging with entrepreneurs about topics ranging from strategy to finance, management, business models and corporate governance.
In addition, I’m also a fan of organisations and processes.

More specifically, as an Investment Manager at TheClubDeal, I’m helping the management of companies like YUST in their growth projects:
- preparation of the next fundraising
- coordination of investor relations
- contribution to financial planning, business model optimisation and definition of strategy

In my Executive Partner and associate role, I might qualify as an organisation freak. I like to set up pragmatic processes in order to continuously collectively improve and support the transformation of TheClubDeal from a rather small investment company (back in 2016) to an investment powerhouse. This process orientation is most probably the heritage of my 5 years spent at UBS in different managing roles (project manager and sales manager) before I joined TheClubDeal at its inception.

By combining decades of experience as an entrepreneur and CEO in the health and fitness sector with an inspiring holistic worldview, I undertake activities that promote health and happiness.

Holmes Place, the leading premium European fitness chain, was founded 40 years ago by my father, Allan Fisher, and represented a ground-breaking approach at the time. Holmes Place continues to focus on innovation that best supports its members to improve and enjoy their health and fitness. Holmes Place Brands, leverages the experience and network built by Holmes Place to identify and partner with exciting and innovative health and fitness offerings globally, these currently include: TRIB3, Evo Fitness and !CON.

10+ Years of tangible clinical research & innovation in general thoracic disease management (Lung & Esophagus).
8+ Years of Cross-Functional Team Leadership, solving problems in surgical thoracic disease management.
7+ Years of Demonstrated Product Development Team Leadership in Surgical Device Design.
12+ Years of demonstrated growth and progressive technical responsibility in Electrical Engineering Design.

José Pedro was named World's Top 70 Health AI Brains and Top 20 Portuguese World-Changer. He's globally recognized for having transformed some of the most complex healthcare organizations by leveraging Data & AI across large hospitals and retail health diagnostics. He pioneered a clinical 560 billion data points platform that monitored 1100 beds in real-time and could predict up to 30% of ICU admissions 7 days earlier, while helping to reduce Hospital Acquired Infections. His groundbreaking work in several institutions was awarded the Microsoft U.S Global Health Innovation Award (MSHUG) and HIMSS Outstanding Digital Healthcare award, recognized with an INSEAD Case Study on Data Intelligence for Medical Diagnostics, and highlighted by the European Commissioner as an exceptional use-case of leveraging Machine Learning to impact patient care. He won Harvard's Competing in the Age of AI competition and was the Health AI Keynote speaker at the leading GenAI conference in Boston, gaiworld.com.

Bio coming soon.